April 15, 2021
Eli Lilly Japan’s JAK inhibitor Olumiant (baricitinib) was added to the review roster of a key heath ministry advisory panel for its April 21 meeting for the treatment of COVID-19 in combination with Gilead Sciences’ antiviral Veklury (remdesivir). The Pharmaceutical...read more